Annual Drug Patent Expirations for LATISSE
Latisse is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for LATISSE.
This drug has thirty-five patent family members in eleven countries.
The generic ingredient in LATISSE is bimatoprost. One supplier is listed for this compound. Additional details are available on the bimatoprost profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
